The mRNA technology behind Moderna’s Covid vaccine reaches the flu
Summary
The FDA approved a new flu vaccine called mFlusiva for people aged 50 and older. This vaccine uses mRNA technology, the same science behind Moderna’s Covid-19 vaccine, and offers a faster way to make flu shots with potentially better protection.Key Facts
- mFlusiva is the first flu vaccine made with mRNA technology approved by the FDA.
- It is for adults aged 50 years or older.
- Moderna expects the vaccine to be available soon at some pharmacies.
- The vaccine reduced flu cases by about 27% compared to a common flu vaccine in people aged 50 to 64.
- For people 65 and older, mFlusiva received accelerated approval and is still under further study.
- Side effects include injection site pain, fever, headache, tiredness, and aches, which were somewhat more common than with existing flu vaccines.
- mRNA technology allows faster vaccine production, which is helpful if flu viruses change quickly.
- The FDA initially delayed approval but later reversed the decision after independent advisers recommended it.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
